期刊文献+

血清和肽素对急性心肌梗死的早期诊断价值

Early Diagnostic Value of Serum Copeptin in Acute Myocardial Infarction
下载PDF
导出
摘要 目的探究血清和肽素对急性心肌梗死的早期诊断价值。方法对2016年4月至2017年8月黑龙江省医院南岗分院收治的84例疑似急性心肌梗死患者进行病情回顾分析。将患者平均分为观察组与对照组,各42例,观察组行和肽素联合肌钙蛋白I水平检测,对照组行肌钙蛋白I水平检测。对比两组诊断价值。结果发病时间4 h内,观察组较对照组诊断灵敏度显著增加,特异性显著下降(P<0.05)。肌钙蛋白I水平在患者胸痛发作6 h后升高,24 h为最大值。和肽素在患者胸痛发作4 h内升高,6 h后逐渐下降。结论和肽素联合肌钙蛋白I检测对发病4 h内急性心肌梗死患者病情的诊断具有良好的灵敏度。 Objective To explore the early diagnostic value of serum copeptin in acute myocardial infarction.Methods A total of patients with suspected acute myocardial infarction admitted to Nangang Branch of Heilongjiang Hospital from April 2016 to August 2017 were retrospectively analyzed.The patients were divided into the observation group and control group,42 cases in each group.The copeptin and troponin I levels of the observation group were detected,while the troponin I level of the control group was detected.The specificity and sensitivity of the two groups were compared.Results Within 4 h of onset,the diagnostic sensitivity of the observation group was higher than the control group,and the diagnostic specificity of the observation group was lower than the control group(P<0.05).Troponin I levels increased 6 h after the onset of chest pain,with a maximum of 24 h.And copeptin increased within 4 h after the onset of chest pain,and decreased gradually after 6 h.Conclusion The detection of troponin I combined with copeptin has a good sensitivity in the diagnosis of patients with acute myocardial infarction within 4 h of onset.
作者 杨艳 YANG Yan(Nangang Branch of Heilongjiang Hospital,Harbin,Heilongjiang 150000,China)
出处 《大医生》 2019年第16期84-85,共2页 Doctor
基金 血清和肽素对急性心肌梗死早期诊断及预后的评估(黑龙江省卫生计生委科研课题:2016-500)。
关键词 血清和肽素 急性心肌梗死 肌钙蛋白I 诊断 serum copeptin acute myocardial infarction troponin I diagnosis
  • 相关文献

参考文献9

二级参考文献73

  • 1无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3686
  • 2JeyabalanA, Shroff SG, Novak J, et al. The vascular actions of relaxin[J]. Adv Exp Med Biol,2007,612:65-87.
  • 3Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin [J]. Am J Physiol Regul Integr Comp Physiol , 2011,301 (2) : 267-275.
  • 4Dschietzig T, Teichman S, Unemori E, et al. Intravenousrecombinant humanrelaxin in compensated heart failure: asafety, tolerability and pharmacodynamic trial [J]. J Card Fail,2009,15(3) : 182-190.
  • 5Teerlink JR, Metra M, Felker GM, et al. Relaxin for thetreatment of patients with acute heart failure (Pre- RELAX- AHF ): a multicentre, randomized, placebo- controlled,parallel-group, dose-finding phase 1I b study[J]. Lancet,2009, 373(9673) :1429-1439.
  • 6Svendsen AM, Zalesko A, Konig J, et al. Negativecooperativit y in H2 relaxin binding to a dimericrelaxin family peptidereceptorl [ J 1. Mol Cell Endocrinol, 2008,296 (1-2) : 10-17.
  • 7TeerlinkJR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF) : a randomised, placebo-controlled trial[J]. Lancet, 2013 ,381 (9860) :29-39.
  • 8Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes[J]. J Am Coll Cardiol, 2013, 61 (2) : 196-206.
  • 9Cotter G, Milo O, Davison BA. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond[J]. Curt Heart Fail Rep,2014,1l(1 ) = 19-30.
  • 10O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure [J]. N Engl J Med,2011,365(1) :32-43.

共引文献5013

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部